Journal Article

Effectiveness and Safety of Apatinib Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer

Ye, Jian-Xin, Zheng, Chao-Hui, Li, Ping, Zang, Wei-Dong, Lin, Wei, You, Jun, Huang, Chang-Ming, Xu, Yan-Chang, Cai, Li-Sheng, Xu, Jian-Hua, Tang, Yi-Hui, Lin, Jian-Xian, Cai, Jian-Chun, Xie, Jian-Wei, Xue, Fang-Qin

2021

Overview

Apatinib is a novel treatment option for chemotherapy-refractory advanced gastric cancer (GC), but it has not been evaluated in patients with locally advanced GC. To investigate the effectiveness and safety of apatinib combined with S-1 plus oxaliplatin (SOX) as a neoadjuvant treatment for locally advanced GC. This multicenter, prospective, single-group, open-label, phase 2 nonrandomized controlled trial was conducted in 10 centers in southern China. Patients with M0 and either clinical T2 to T4 or N+ disease were enrolled between July 1, 2017, and June 30, 2019. Statistical analysis was performed from December 1, 2019, to January 31, 2020. Eligible patients received apatinib (500 mg orally once daily on days 1 to 21 and discontinued in the last cycle) plus SOX (S-1: 40-60 mg orally twice daily on days 1 to 14; oxaliplatin: 130 mg/m2 intravenously on day 1) every 3 weeks for 2 to 5 cycles. A D2 gastrectomy was performed 2 to 4 weeks after the last cycle. The primary end point was R0 resection rate. Secondary end points were the response rate, toxic effects, and surgical outcome. A total of 48 patients (mean [SD] age, 63.2 [8.2] years; 37 men [77.1%]) were enrolled in this study. Forty patients underwent surgery (38 had gastrectomy, and 2 had exploratory laparotomy), with an R0 resection rate of 75.0% (95% CI, 60.4%-86.4%). The radiologic response rate was 75.0%, and T downstaging was observed in 16 of 44 patients (36.4%). The pathological response rate was 54.2% (95% CI, 39.2%-68.6%); moreover, this rate was significantly higher in patients who achieved a radiologic response compared with those who did not (12 [80.0%] vs 1 [20.0%]; P = .03) and in those who had an Eastern Cooperative Oncology Group Performance Status score of 0 (20 [76.9%] vs 10 [45.5%]; P = .03) or had tumors located in the upper one-third of the stomach (16 [61.5%] vs 7 [31.8%]; P = .04). Patients who achieved a pathological response (vs those who did not) had significantly less blood loss (median [range]: 60 [10-200] mL vs 80 [20-300] mL; P = .04) and significantly more lymph nodes harvested (median [range]: 40 [24-67] vs 32 [19-51]; P = .04) during surgery. Postoperative complications were observed in 7 of 38 patients (18.4%). Grade 3 toxic effects occurred in 16 of 48 patients (33.3%), and no grade 4 toxic effects or preoperative deaths were observed. This nonrandomized controlled trial found that apatinib combined with SOX was effective and had an acceptable safety profile as a neoadjuvant treatment for locally advanced GC. A large-scale randomized clinical trial may be needed to confirm the findings. ClinicalTrials.gov Identifier: NCT03192735.

• Publisher: American Medical Association
• Subject: Adult / Antineoplastic Agents - standards / Antineoplastic Agents - therapeutic use / Chemotherapy / China - epidemiology / Female / Gastric cancer / Gastrointestinal surgery / Humans / Male / Middle Aged / Neoadjuvant Therapy - methods / Neoadjuvant Therapy - standards / Neoadjuvant Therapy - statistics & numerical data / Oncology / Online Only / Original Investigation / Oxaliplatin - standards / Oxaliplatin - therapeutic use / Prospective Studies / Pyridines - standards / Pyridines - therapeutic use / Response rates / Stomach Neoplasms - epidemiology / Stomach Neoplasms - therapy / Treatment Outcome